BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor

BIOCRYST PHARMACEUTICALS INC

Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.
Charlie Gayer appointed President (Aug 1, 2025) and CEO (Jan 1, 2026); previously CCO.
Gayer's base salary rises to $675k as President; expected $775k as CEO with 85% AIP target.
Gayer elected to board effective Jan 1, 2026; board size increased from nine to ten.
Stonehouse cited no disagreement; transition follows succession planning process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.